HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Selective inhibition of the master regulator transcription factor Egr-1 with catalytic oligonucleotides reduces myocardial injury and improves left ventricular systolic function in a preclinical model of myocardial infarction.

AbstractBACKGROUND:
Egr-1 is implicated in the pathogenesis of myocardial ischemia-reperfusion injury. The aim of this study was to ascertain the effectiveness of intracoronary delivery of DNAzyme targeting the transcription factor Egr-1 at reperfusion following experimental myocardial ischemia.
METHODS AND RESULTS:
Functional DNAzyme targeting Egr-1 or a size-matched scrambled control were delivered via the intracoronary route immediately on reperfusion after 60 minutes' balloon occlusion of the left anterior descending coronary artery in a pig model of myocardial I/R injury (n=7 per treatment group). Heart function and extent of myocardial infarction were determined following intervention by echocardiography and cardiac magnetic resonance imaging, respectively. Hearts were removed and examined for molecular and histological markers of inflammation and apoptosis. Administration of functional DNAzyme led to an overall decrease in the expression of inflammatory markers including intracellular adhesion molecule-1, tissue factor, and complement 3, with associated decreases in the extent of neutrophil infiltration, oxidative damage, and subsequent apoptosis within the infarct border zone. Functional significance was indicated by an increase in salvaged left ventricular myocardium (P=0.012), ejection fraction (P=0.002), and fractional area change (P=0.039) in the functional DNAzyme-treated group compared with the control.
CONCLUSIONS:
Egr-1 silencing through intracoronary delivery of a targeting DNAzyme at the time of reperfusion following acute myocardial ischemia decreases myocardial inflammation and apoptosis leading to improved cardiac function.
AuthorsBenjamin S Rayner, Gemma A Figtree, Tharani Sabaretnam, Ping Shang, Jawad Mazhar, James C Weaver, William N Lay, Paul K Witting, Stephen N Hunyor, Stuart M Grieve, Levon M Khachigian, Ravinay Bhindi
JournalJournal of the American Heart Association (J Am Heart Assoc) Vol. 2 Issue 4 Pg. e000023 (Jul 31 2013) ISSN: 2047-9980 [Electronic] England
PMID23902638 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • DNA, Catalytic
  • Early Growth Response Protein 1
  • Inflammation Mediators
  • Oligonucleotides
  • RNA, Messenger
Topics
  • Animals
  • Apoptosis
  • DNA, Catalytic (administration & dosage)
  • Disease Models, Animal
  • Down-Regulation
  • Early Growth Response Protein 1 (genetics, metabolism)
  • Echocardiography
  • Inflammation Mediators (metabolism)
  • Magnetic Resonance Imaging, Cine
  • Male
  • Myocardial Infarction (diagnosis, enzymology, genetics, physiopathology, prevention & control)
  • Myocardial Reperfusion Injury (diagnosis, enzymology, physiopathology, prevention & control)
  • Myocardium (enzymology, pathology)
  • Neutrophil Infiltration
  • Oligonucleotides (administration & dosage)
  • Oxidative Stress
  • RNA, Messenger (metabolism)
  • Stroke Volume
  • Swine
  • Systole
  • Time Factors
  • Ventricular Dysfunction, Left (diagnosis, enzymology, genetics, physiopathology, prevention & control)
  • Ventricular Function, Left

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: